CRISPR Therapeutics AG (NASDAQ:CRSP) Receives Average Recommendation of “Hold” from Analysts

Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) have earned a consensus rating of “Hold” from the eighteen ratings firms that are currently covering the firm, Marketbeat reports. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and ten have given a buy rating to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $64.5294.

CRSP has been the topic of several recent analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of CRISPR Therapeutics in a report on Wednesday, January 21st. Evercore restated an “outperform” rating and set a $74.00 price target on shares of CRISPR Therapeutics in a report on Friday, February 13th. Chardan Capital lifted their price target on shares of CRISPR Therapeutics from $74.00 to $76.00 and gave the company a “buy” rating in a research report on Saturday, February 14th. Citigroup reiterated a “buy” rating on shares of CRISPR Therapeutics in a report on Monday, February 16th. Finally, TD Cowen increased their price objective on CRISPR Therapeutics from $40.00 to $45.00 and gave the stock a “hold” rating in a research report on Friday, February 13th.

Insider Transactions at CRISPR Therapeutics

In other news, General Counsel James R. Kasinger sold 3,450 shares of the stock in a transaction on Monday, March 16th. The stock was sold at an average price of $48.26, for a total transaction of $166,497.00. Following the completion of the transaction, the general counsel directly owned 91,240 shares in the company, valued at approximately $4,403,242.40. This represents a 3.64% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Samarth Kulkarni sold 60,000 shares of the firm’s stock in a transaction dated Thursday, January 22nd. The stock was sold at an average price of $60.23, for a total value of $3,613,800.00. Following the sale, the chief executive officer directly owned 134,201 shares of the company’s stock, valued at $8,082,926.23. The trade was a 30.90% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 128,626 shares of company stock worth $7,126,807. 4.10% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On CRISPR Therapeutics

A number of institutional investors have recently made changes to their positions in the stock. Mcguire Capital Advisors Inc. acquired a new position in shares of CRISPR Therapeutics in the 4th quarter worth approximately $25,000. Ramirez Asset Management Inc. acquired a new stake in CRISPR Therapeutics in the 4th quarter valued at approximately $26,000. Optiver Holding B.V. raised its position in CRISPR Therapeutics by 71.4% in the third quarter. Optiver Holding B.V. now owns 504 shares of the company’s stock valued at $33,000 after purchasing an additional 210 shares during the period. Thompson Investment Management Inc. purchased a new stake in CRISPR Therapeutics in the third quarter valued at approximately $33,000. Finally, Strategic Advocates LLC acquired a new position in CRISPR Therapeutics during the third quarter worth $34,000. 69.20% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about CRISPR Therapeutics

Here are the key news stories impacting CRISPR Therapeutics this week:

• Positive Sentiment: CASGEVY commercial momentum — Patient starts for CASGEVY nearly tripled year‑over‑year and CRISPR plans a H1 2026 pediatric label filing, supporting revenue growth potential and commercial credibility. CRISPR Therapeutics Balances CASGEVY Momentum With Early Pipeline Uncertainty
• Positive Sentiment: Clinical validation for CTX310 — Early CTX310 data were published in the New England Journal of Medicine and the program is moving into Phase 1b, adding clinical proof‑of‑concept for a key cardiovascular asset. CRISPR Therapeutics Balances CASGEVY Momentum With Early Pipeline Uncertainty
• Neutral Sentiment: $550M convertible note — The company raised US$550M via 1.7308% convertible senior notes due 2031, which materially boosts cash runway to fund commercialization and trials but introduces potential future dilution if converted. How Investors May Respond To CRISPR Therapeutics (CRSP) $550 Million Convertible Note Boost To Cash Reserves
• Neutral Sentiment: Analyst stance — Piper Sandler reaffirmed an Overweight rating, which is supportive but not uncommon after mixed news; keep an eye on analyst commentary around upcoming data readouts. Piper Sandler Reaffirms Overweight Rating for CRISPR Therapeutics (NASDAQ:CRSP)
• Neutral Sentiment: Short‑interest data appear inconsistent — Recent reports show zero shares and NaN changes, suggesting a data error or reporting lag; this is not currently providing a clear signal on positioning. (Data entries: 3/19–3/20)
• Negative Sentiment: Pipeline uncertainty and timing risk — Coverage notes that while CASGEVY sales are encouraging, several pipeline candidates are early‑stage and investors will wait for additional clinical readouts over the next 12 months before revising convictions. CRISPR Therapeutics Balances CASGEVY Momentum With Early Pipeline Uncertainty
• Negative Sentiment: Recent share weakness — Multiple market summaries reported multi‑day declines (mid‑ to late‑March), reflecting investor caution despite positive commercial and financing headlines; short‑term price action likely driven by sentiment and upcoming catalysts. CRISPR Therapeutics AG (CRSP) Falls More Steeply Than Broader Market Zacks: CRSP Registers a Bigger Fall Than the Market

CRISPR Therapeutics Stock Down 1.5%

NASDAQ CRSP opened at $46.24 on Monday. The business’s fifty day simple moving average is $53.26 and its 200-day simple moving average is $57.12. The firm has a market cap of $4.44 billion, a PE ratio of -7.09 and a beta of 1.71. CRISPR Therapeutics has a 52 week low of $30.04 and a 52 week high of $78.48.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings data on Thursday, February 12th. The company reported ($1.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.15) by ($0.22). CRISPR Therapeutics had a negative net margin of 16,569.77% and a negative return on equity of 26.31%. The firm had revenue of $0.86 million during the quarter, compared to analysts’ expectations of $4.72 million. During the same period in the prior year, the company posted ($1.01) EPS. The company’s revenue for the quarter was down 97.8% compared to the same quarter last year. Research analysts expect that CRISPR Therapeutics will post -5.16 EPS for the current year.

About CRISPR Therapeutics

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.